权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Nanomedicine-based Chemo-Immunotherapy for the Treatment of Pediatric Brain Cancer

基于纳米药物的化学免疫疗法治疗小儿脑癌

基本信息

批准号：
22K12833
负责人：
劉学瑩
金额：
$ 2.66万
依托单位：
Kawasaki Institute of Industrial Promotion Innovation Center of NanoMedicine
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2022
资助国家：
日本
起止时间：
2022-04-01 至 2025-03-31
项目状态：
未结题

来源：
https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22K12833/
关键词：
Nanomedicine chemo-immunotherapy medulloblastoma childhood cancers Chemo-immunotherapy pH-triggered Medulloblastoma

项目摘要

For this project, we proposed to generate and validate a syngeneic mouse model of medulloblastoma and understand the potential of a tumor pH-sensitive NM loaded with ICD-inducing drug modulating tumor immune environment against MB. Towards these aims, we managed to achieve the following research outcomes-Generate and validate a syngeneic mouse model of medulloblastoma (MB) - Dr. Robert Wechsler-Reya's laboratory at Sanford Burnham Prebys Medical Discovery Institute, CA, United States, established several MB syngeneic models. One of the collaborating investigators (Co-I), Dr. Sabina Quader, could successfully initiate a research collaboration with Dr. Wechsler-Reya. Through this collaboration we created a syngeneic mouse model of MB in our laboratory. We consider this a significant advancement in our MB-related research, as developing a syngeneic mouse model is critical for immune-related studies against MB.Collect preliminary research results using tumor pH-sensitive NM loaded with ICD-inducing drug against MB syngeneic model- We have successfully completed our preliminary research studies using tumor pH-sensitive NM loaded with ICD-inducing drug against MB syngeneic model. Based on the results of these studies, we are now moving on to the next phase of studies, where we are considering examining the potential of using immune checkpoint inhibitors.

对于这个项目，我们建议生成并验证髓母细胞瘤的同基因小鼠模型，并了解负载 ICD 诱导药物的肿瘤 pH 敏感 NM 的潜力，该药物可调节针对 MB 的肿瘤免疫环境。为了实现这些目标，我们成功实现了以下研究成果——生成并验证髓母细胞瘤（MB）同系小鼠模型——美国加利福尼亚州桑福德伯纳姆普雷比斯医学发现研究所的Robert Wechsler-Reya博士实验室建立了多个MB同系模型。其中一位合作研究人员 (Co-I) Sabina Quader 博士可以成功地与 Wechsler-Reya 博士开展研究合作。通过这次合作，我们在实验室创建了 MB 的同基因小鼠模型。我们认为这是我们MB相关研究的重大进展，因为开发同系小鼠模型对于针对MB的免疫相关研究至关重要。使用负载ICD诱导药物的肿瘤pH敏感NM针对MB同系模型收集初步研究结果 - 我们已经成功完成了针对MB同系模型使用负载ICD诱导药物的肿瘤pH敏感NM的初步研究结果。根据这些研究的结果，我们现在正在进入下一阶段的研究，我们正在考虑检查使用免疫检查点抑制剂的潜力。